Free Trial
NASDAQ:IFRX

InflaRx Q2 2023 Earnings Report

InflaRx logo
$0.86 0.00 (-0.45%)
Closing price 04:00 PM Eastern
Extended Trading
$0.89 +0.03 (+3.13%)
As of 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

InflaRx EPS Results

Actual EPS
-$0.15
Consensus EPS
-$0.36
Beat/Miss
Beat by +$0.21
One Year Ago EPS
N/A

InflaRx Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

InflaRx Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Thursday, August 10, 2023
Conference Call Time
5:00AM ET

Upcoming Earnings

InflaRx's Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

InflaRx Earnings Headlines

“All the land that you see I will give to you and your offspring forever…”
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.
See More InflaRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like InflaRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on InflaRx and other key companies, straight to your email.

About InflaRx

InflaRx (NASDAQ:IFRX) NV is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutic antibodies targeting components of the innate immune system. The company’s lead program is vilobelimab (IFX-1), a monoclonal antibody that selectively inhibits the complement factor C5a, a potent driver of inflammation. InflaRx is advancing vilobelimab in multiple indications, including hidradenitis suppurativa, paroxysmal nocturnal hemoglobinuria and other rare and severe inflammatory diseases, with both ongoing and planned clinical trials.

Founded in 2007 and headquartered in Jena, Germany, InflaRx maintains operational offices in the United States to support its North American development and regulatory activities. The company has established strategic collaborations for manufacturing and clinical research in Europe and North America, ensuring access to state-of-the-art facilities and patient populations. InflaRx completed its initial public offering on the NASDAQ stock exchange in 2019 to accelerate its pipeline advancement and expand global clinical programs.

Under the leadership of Chief Executive Officer Jan Schmidt, InflaRx is led by a management team with extensive experience in immunology, drug development and regulatory affairs. The company’s board and scientific advisory group include industry veterans from biotechnology and pharmaceutical backgrounds who guide strategy and clinical program design. InflaRx remains committed to translating its complement-modulating platform into novel therapies that address unmet needs in inflammatory and autoimmune diseases worldwide.

View InflaRx Profile

More Earnings Resources from MarketBeat